<DOC>
	<DOCNO>NCT00458276</DOCNO>
	<brief_summary>Endothelin-1 powerful substance may involve cause hemodynamic instability ( problem relate unstable blood pressure ) open heart surgery . Tezosentan investigational intravenous drug block endothelin receptor . This clinical trial ass potential benefit tezosentan compare placebo treatment patient undergo open heart surgery cardiopulmonary bypass ( CPB ) . Treatment time start surgery 24 hour .</brief_summary>
	<brief_title>Study Efficacy Safety Tezosentan Patients With Pre-operative Pulmonary Hypertension , Due Left Heart Disease , Undergoing Open Heart Surgery</brief_title>
	<detailed_description>Endothelin-1 level increase cardiac surgery cardiopulmonary bypass ( CPB ) , associate many deleterious consequence , include increase pulmonary arterial pressure ( PAP ) , increase pulmonary vascular resistance ( PVR ) , reduce myocardial contractility , ultimately right ventricular failure . Right ventricular failure wean CPB increase risk mortality morbidity , especially patient elevate PAP prior cardiac surgery . Endothelin receptor antagonist ( ERAs ) show decrease PVR pulmonary arterial pressure ( PAP ) , improve right ventricular function patient pulmonary arterial hypertension . In animal model , ERAs show decrease incidence post-bypass pulmonary hypertensive crisis . The primary objective trial demonstrate tezosentan , dual ERA , reduce incidence clinically relevant right ventricular failure patient pre-operative pulmonary hypertension , due leave heart disease , undergo CPB .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>Patients â‰¥ 18 year age Male female patient ( female childbearing potential must surgically sterilize use reliable method contraception ) . Patients undergo complex* cardiac surgery CPB systolic PAP &gt; 40 mmHg mean PAP &gt; 30 mmHg ( *surgery 2 valve , 1 valve revascularization , reoperation valve ) Patients undergoing cardiac surgery CPB preoperative pulmonary hypertension due leave heart disease systolic PAP &gt; 60 mmHg Signed write informed consent Systolic blood pressure &lt; 100 mmHg Significant chronic lung disease Emergency surgery Pregnant/breastfeeding Investigational drug use within 28 day prior randomization Complex adult congenital heart disease . Severe concomitant illness limit life expectancy &lt; 6 month Participation device study affect outcome study Preoperative use balloon pump , inotropes/vasopressors , treatment pulmonary arterial hypertension Known hypersensitivity tezosentan drug class , excipients Severe liver impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Left side heart disease</keyword>
	<keyword>Elevated pulmonary arterial pressure</keyword>
	<keyword>Right ventricular failure</keyword>
	<keyword>Cardiac surgery</keyword>
	<keyword>heart-lung machine</keyword>
	<keyword>cardiopulmonary bypass</keyword>
	<keyword>tezosentan</keyword>
	<keyword>Actelion</keyword>
</DOC>